Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2022 Filed Feb 28, 2022 21:38 UTC |
Zakrowski Donald AChief Accounting Officer
|
SaleCommon Stock | 1,660 | $243.84 | $404,774.40 |
DisclosureSEC source: 0000059478-22-000086 · wf-form4_164608421046516.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,274 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2021. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:01 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 41 | $239.13 | $9,804.33 |
DisclosureSEC source: 0000059478-22-000073 · wf-form4_164574009335560.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,883 F1 · balance_after: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:04 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 53 | $239.13 | $12,673.89 |
DisclosureSEC source: 0000059478-22-000075 · wf-form4_164574023518687.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,591 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:06 UTC |
JOHNSON KIMBERLY HDirector
|
GrantCommon Stock | 40 | $239.13 | $9,565.20 |
DisclosureSEC source: 0000059478-22-000077 · wf-form4_164574038793543.xml · nonDerivative · entry 1 JOHNSON KIMBERLY H · CIK 0001658089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:09 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 41 | $239.13 | $9,804.33 |
DisclosureSEC source: 0000059478-22-000079 · wf-form4_164574055973722.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:11 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 47 | $239.13 | $11,239.11 |
DisclosureSEC source: 0000059478-22-000081 · wf-form4_164574069068616.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,189 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:40 UTC |
Yuffa IlyaSVP & President, LLY Int'l
|
SaleCommon Stock | 1,000 | $242.58 | $242,580.00 |
DisclosureSEC source: 0000059478-22-000063 · wf-form4_164513402373017.xml · nonDerivative · entry 2 Yuffa Ilya · CIK 0001826001 · SVP & President, LLY Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2021. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC |
Van Naarden JacobSVP, CEO LoxoONC, Pres LlyONC
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,461 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC |
Van Naarden JacobSVP, CEO LoxoONC, Pres LlyONC
|
Tax withholdingCommon Stock | 2,186 | $243.84 | $533,034.24 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,967 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC |
Van Naarden JacobSVP, CEO LoxoONC, Pres LlyONC
|
Exercise / conversionCommon Stock | 5,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:40 UTC |
Yuffa IlyaSVP & President, LLY Int'l
|
SaleCommon Stock | 1,000 | $237.45 | $237,450.00 |
DisclosureSEC source: 0000059478-22-000063 · wf-form4_164513402373017.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · SVP & President, LLY Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2021. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:03 UTC |
Ashkenazi AnatSVP & CFO
|
GrantCommon Stock | 5,752 | $243.27 | $1,399,289.04 |
DisclosureSEC source: 0000059478-22-000034 · wf-form4_164462057536904.xml · nonDerivative · entry 1 Ashkenazi Anat · CIK 0001761679 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,427 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:06 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000036 · wf-form4_164462075615820.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,264 Underlying: Common Stock · 7,264 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:06 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 12,339 | $243.27 | $3,001,708.53 |
DisclosureSEC source: 0000059478-22-000036 · wf-form4_164462075615820.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,631 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:09 UTC |
Hakim AnatSVP, GC & Secretary
|
GrantRestricted Stock Unit · Derivative | 7,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000038 · wf-form4_164462096325305.xml · derivative · entry 2 Hakim Anat · CIK 0001685556 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,646 Underlying: Common Stock · 7,646 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:12 UTC |
Hernandez EdgardoSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 5,435 | $243.27 | $1,322,172.45 |
DisclosureSEC source: 0000059478-22-000040 · wf-form4_164462114168110.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,610 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:16 UTC |
Jonsson PatrikSVP&Pres, LLY Imm, LLY USA&CCO
|
GrantRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000042 · wf-form4_164462137367209.xml · derivative · entry 3 Jonsson Patrik · CIK 0001786054 · SVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,690 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:16 UTC |
Jonsson PatrikSVP&Pres, LLY Imm, LLY USA&CCO
|
GrantCommon Stock | 2,036 | $243.27 | $495,297.72 |
DisclosureSEC source: 0000059478-22-000042 · wf-form4_164462137367209.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · SVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,710 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:19 UTC |
Mason Michael BSr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000044 · wf-form4_164462154515553.xml · derivative · entry 3 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,690 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:19 UTC |
Mason Michael BSr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 2,612 | $243.27 | $635,421.24 |
DisclosureSEC source: 0000059478-22-000044 · wf-form4_164462154515553.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,506 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:22 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000046 · wf-form4_164462174983605.xml · derivative · entry 5 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102 Underlying: Common Stock · 2,102 shares Expires 2023-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:22 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantCommon Stock | 3,294 | $243.27 | $801,331.38 |
DisclosureSEC source: 0000059478-22-000046 · wf-form4_164462174983605.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,240 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:25 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 3,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000048 · wf-form4_164462189343178.xml · derivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,154 Underlying: Common Stock · 3,154 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:25 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
GrantCommon Stock | 5,309 | $243.27 | $1,291,520.43 |
DisclosureSEC source: 0000059478-22-000048 · wf-form4_164462189343178.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,244 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:28 UTC |
Ricks David ADirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 47,786 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000050 · wf-form4_164462211639564.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,786 Underlying: Common Stock · 47,786 shares Expires 2023-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:28 UTC |
Ricks David ADirector · President & CEO
|
GrantCommon Stock | 68,004 | $243.27 | $16,543,333.08 |
DisclosureSEC source: 0000059478-22-000050 · wf-form4_164462211639564.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,783 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:31 UTC |
Skovronsky DanielSVP, CS&MO & Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000052 · wf-form4_164462229151272.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,675 Underlying: Common Stock · 15,675 shares Expires 2023-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:31 UTC |
Skovronsky DanielSVP, CS&MO & Pres. LRL
|
GrantCommon Stock | 22,581 | $243.27 | $5,493,279.87 |
DisclosureSEC source: 0000059478-22-000052 · wf-form4_164462229151272.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,559 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:35 UTC |
Weems AlonzoSVP, ERM & CECO
|
GrantCommon Stock | 3,731 | $243.27 | $907,640.37 |
DisclosureSEC source: 0000059478-22-000054 · wf-form4_164462253456266.xml · nonDerivative · entry 1 Weems Alonzo · CIK 0001869672 · SVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,792 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:38 UTC |
White Anne E.SVP & Pres-Lilly Neuroscience
|
GrantRestricted Stock Unit · Derivative | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000056 · wf-form4_164462270168794.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,264 Underlying: Common Stock · 7,264 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:38 UTC |
White Anne E.SVP & Pres-Lilly Neuroscience
|
GrantCommon Stock | 11,348 | $243.27 | $2,760,627.96 |
DisclosureSEC source: 0000059478-22-000056 · wf-form4_164462270168794.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,352 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:42 UTC |
Yuffa IlyaSVP & President, LLY Int'l
|
GrantCommon Stock | 3,275 | $243.27 | $796,709.25 |
DisclosureSEC source: 0000059478-22-000058 · wf-form4_164462288785243.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · SVP & President, LLY Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,624 Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:45 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 2,947 | $243.27 | $716,916.69 |
DisclosureSEC source: 0000059478-22-000060 · wf-form4_164462312066313.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,934 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:46 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 56,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000022 · wf-form4_164392474521378.xml · derivative · entry 5 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,205 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:46 UTC |
Ricks David ADirector · President & CEO
|
Tax withholdingCommon Stock | 25,170 | $245.39 | $6,176,466.30 |
DisclosureSEC source: 0000059478-22-000022 · wf-form4_164392474521378.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,779 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:46 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionCommon Stock | 56,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000022 · wf-form4_164392474521378.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC |
Skovronsky DanielSVP, CS&MO & Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,735 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC |
Skovronsky DanielSVP, CS&MO & Pres. LRL
|
Tax withholdingCommon Stock | 8,437 | $245.39 | $2,070,355.43 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,978 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC |
Skovronsky DanielSVP, CS&MO & Pres. LRL
|
Exercise / conversionCommon Stock | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:55 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000026 · wf-form4_164392526851459.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,170 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:55 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 4,554 | $245.39 | $1,117,506.06 |
DisclosureSEC source: 0000059478-22-000026 · wf-form4_164392526851459.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,292 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:55 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 10,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000026 · wf-form4_164392526851459.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:04 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000030 · wf-form4_164392587950558.xml · derivative · entry 3 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,416 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:04 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 2,010 | $245.39 | $493,233.90 |
DisclosureSEC source: 0000059478-22-000030 · wf-form4_164392587950558.xml · nonDerivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,935 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:04 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 4,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000030 · wf-form4_164392587950558.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:59 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000028 · wf-form4_164392557628191.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,676 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:59 UTC |
Norton JohnaSenior VP, Global Quality
|
Tax withholdingCommon Stock | 1,194 | $245.39 | $292,995.66 |
DisclosureSEC source: 0000059478-22-000028 · wf-form4_164392557628191.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,946 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:59 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionCommon Stock | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000028 · wf-form4_164392557628191.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:09 UTC |
White Anne E.SVP & Pres-Lilly Neuroscience
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000032 · wf-form4_164392615619605.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,368 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:09 UTC |
White Anne E.SVP & Pres-Lilly Neuroscience
|
Tax withholdingCommon Stock | 4,204 | $245.39 | $1,031,619.56 |
DisclosureSEC source: 0000059478-22-000032 · wf-form4_164392615619605.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,004 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.